Reunion Weekend Keynote Speakers

ENVIRONMENTAL EXPOSURES AND HEALTH OUTCOMES AMONG HISTORICALLY MARGINALIZED COMMUNITIES

Friday, June 9, at 11 a.m.

Dr. Hosgood’s research focuses on identifying associations between environmental exposures and adverse health outcomes, emphasizing cancer and gene-environment interactions. He utilizes advanced population-based and clinical-based methods that integrate observational study designs, cutting-edge exposure assessments, and biomarkers of susceptibility (i.e., genetic data) to explain the complex mechanisms underlying tumorigenesis—the formulation of a tumor. Dr. Hosgood’s session will focus on his work in this area and its impact on historically marginalized communities. Dean is an associate professor and the Atran Foundation chair in epidemiology and population health at the Albert Einstein College of Medicine in the Bronx, NY.

LOVE YOUR BODY

Friday, June 9, at 3 p.m.

Gabrielle Joffie Richards ’03 is brand director for Shapermint, a size-inclusive SupportiveWear brand, and The BodCon—the number one body confidence community in the world. As a licensed body positive coach, she has worked significantly with brands that help empower men and women feel confident within their skin. While in college, Gabrielle noticed a lack of emphasis on body positivity within the fashion industry. This helped pique her interest in owning her narrative and developing an education within the body positive and acceptance space. Gabrielle will present her work and experience in these fields.

HOW PSILOCYBIN MUSHROOMS CAN HELP SAVE THE WORLD

Saturday, June 10, at 1:30 p.m.

The recent upsurge in interest in psilocybin mushrooms by the scientific community is attributable to their extensive use throughout history, widespread use today, and increasing number of clinical studies validating psilocybin as a breakthrough medicine. Come learn about the historical use of mushrooms and psilocybin’s potential for neurological health based on recent results on molecular modes of action. As co-founder and majority shareholder of MycoMedica Life Sciences, PBC, Paul is well positioned with his team to conduct clinical studies based in part on the four U.S. composition patents he recently received on psilocybin discoveries.